Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | TK1 | P04183 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542978 | 0.90 | MAPK1 (0.40) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL16297679 | 0.90 | MAPK1 (0.40) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL7761597 | 0.89 | HPGD (0.41) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL7529489 | 0.89 | HPGD (0.43) | HPGDMAPK1TK1 | |
| SCHEMBL8045900 | 0.87 | TK1 (0.46) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL13577273 | 0.86 | HPGD (0.37) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL18788917 | 0.85 | HPGD (0.40) | HPGDMAPK1TK1 | |
| SCHEMBL3918733 | 0.84 | KMT2A (0.39) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL3918737 | 0.84 | TK1 (0.40) | HPGDMAPK1CA12CA1CA2 | |
| SCHEMBL14528806 | 0.84 | TK1 (0.40) | HPGDMAPK1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | NEUBASE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11124543-B2 | Self-assembled structures composed of monomers of peptide nucleic acid and tunable photonic crystals made therefrom | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2021-09-21 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2017068584-A1 | SELF-ASSEMBLED STRUCTURES COMPOSED OF MONOMERS OF PEPTIDE NUCLEIC ACID AND TUNABLE PHOTONIC CRYSTALS MADE THEREFROM | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-04-27 | — | — | WO | disclosed |
| WO-2006044716-A2 | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER | WASHINGTON UNIVERSITY IN ST.LOUIS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6903074-B1 | Neuromedin b and somatostatin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2005-06-07 | — | — | US | disclosed |
| EP-1189941-A1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2002-03-27 | — | — | EP | disclosed |
| EP-0761681-B1 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AG (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000075186-A1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) | 2000-12-14 | — | — | WO | disclosed |
| US-5977296-A | MONOMERS WITH ALIPHATIC CYCLIC STRUCTURE IN THE BACKBONE; FOR INCREASED CONFORMATION RESTRICTION LEADING TO INCREASED BINDING AFFINITY AND SPECIFICITY; FOR DETECTING POINT MUTATIONS, FOR SUPPRESSING WILD TYPE GENES IN AMPLIFICATION | NIELSEN, PETER E. (DK) | 1999-11-02 | — | — | US | disclosed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0761681-A2 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996020212-A2 | PEPTIDE NUCLEIC ACID INCORPORATING A CHIRAL BACKBONE | BUCHARDT, DORTE (DK) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577396-B2 | Tolan compound | TAP1, GRN, TSG101 | HPGD 3631/4885MAPK1 1259/4885CA12 4772/4885 |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | HPGD 4516/4885MAPK1 2622/4885CA12 326/4885 |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | HPGD 2060/4885MAPK1 3527/4885CA12 4682/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | HPGD 2060/4885MAPK1 3527/4885CA12 4682/4885 |
| US-11124543-B2 | Self-assembled structures composed of monomers of peptide nucleic acid and tunable photonic crystals made therefrom | POLM, RNMT, NPM1 | HPGD 4506/4885MAPK1 2705/4885CA12 1336/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | HPGD 2060/4885MAPK1 3527/4885CA12 4682/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | HPGD 2060/4885MAPK1 3527/4885CA12 4682/4885 |
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | SNRPA1, SNRPA, SNRPE | HPGD 4713/4885MAPK1 4020/4885CA12 4759/4885 |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | SMN1; SMN2, POLRMT, TARDBP | HPGD 4487/4885MAPK1 4676/4885CA12 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.